A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 25-33

  Vergote, Ignace ^a   Schilder, Russell J ^b   Pippitt, Charles H ^c   Wong, Shirley ^d   Gordon, Alan N ^e   Scudder, Sidney ^f   Kridelka, Frederic ^g   Dirix, Luc ^h   Leach, Joseph W ⁱ   Ananda, Sumitra ^j   Nanayakkara, Nuwan ^k   Melara, Rebeca ^l   Bass, Michael B ^l   Litten, Jason ^l   Adewoye, Henry ^l   Wenham, Robert M ^m  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Novant Health Oncology Specialists Winston Salem   (United States)

^d WESTERN HOSPITAL   (Australia)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h SINT AUGUSTINUS HOSPITAL   (Belgium)

ⁱ Virginia Piper Cancer Institute   (United States)

^j ROYAL WOMEN'S HOSPITAL   (Australia)

^k IQVIA   (United States)

^l AMGEN INC   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

more..

Author keywords

Angiogenesis; Angiopoietins; Combination treatments; Dose limiting toxicities; Targeted therapy; Tie2 receptor

Indexed keywords

ANTIBODY; DOXORUBICIN; HEMOGLOBIN; PLATINUM DERIVATIVE; TOPOTECAN; TREBANANIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC ANTIBIOTIC; DNA TOPOISOMERASE INHIBITOR; HYBRID PROTEIN; MACROGOL DERIVATIVE; TRENANANIB;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; APPENDICITIS; AREA UNDER THE CURVE; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ARTICLE; ASCITES; BACKACHE; BLEEDING; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; INSOMNIA; INTESTINE PERFORATION; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OROPHARYNX PAIN; OVARY CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SENSORY NEUROPATHY; SIDE EFFECT; STOMACH PERFORATION; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; WOUND HEALING IMPAIRMENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; DRUG RESISTANCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; RECOMBINANT FUSION PROTEINS; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84908022446     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.003     Document Type: Article

References (40)

1. P.-L. María Eva, C. Teresa, G. Jesús García, and J. Mónica Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer Anticancer Drugs 18 2007 611 617
2. M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
3. G. Ferrandina, M. Ludovisi, D. Lorusso, S. Pignata, E. Breda, and A. Savarese Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896
4. M. Markman Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer Cancer Manag Res 3 2011 219 225
5. A.N. Gordon, M. Tonda, S. Sun, and W. Rackoff Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 2004 1 8
6. M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
7. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286
8. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J Clin Oncol 2014 10.1200/JCO.2013.51.4489
9. P. Witteveen, A. Lortholary, T. Fehm, A. Poveda, A. Reuss, and H. Havsteen Final overall survival (OS) results from AURELIA, an open-label randomized phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC) Eur J Cancer 49 Suppl. 3 2013
10. P. Harter, J. Sehouli, R. Kimmig, J. Rau, F. Hilpert, and C. Kurzeder Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO study group (AGO-OVAR 2.13) Invest New Drugs 31 2013 1499 1504
11. P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, and C. Radziejewski Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 1997 55 60
12. C. Suri, P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, and S. Davis Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
13. L. Eklund, and B.R. Olsen Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling Exp Cell Res 312 2006 630 641
14. J. Oliner, H. Min, J. Leal, D. Yu, S. Rao, and E. You Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 2004 507 516
15. A. Coxon, J. Bready, H. Min, S. Kaufman, J. Leal, and D. Yu Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol Cancer Ther 9 2010 2641 2651
16. R.S. Herbst, D. Hong, L. Chap, R. Kurzrock, E. Jackson, and J.M. Silverman Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors J Clin Oncol 27 2009 3557 3565
17. B.Y. Karlan, A.M. Oza, G.E. Richardson, D.M. Provencher, V.L. Hansen, and M. Buck Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer J Clin Oncol 30 2012 362 371
18. B.J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, and D.S. Bae A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 Eur J Cancer 49 Suppl. 3 2013
19. B. Karabulut, C. Sezgin, M.C. Terek, R. Uslu, U.A. Sanli, and L. Akman Topotecan in platinum-resistant epithelial ovarian cancer Chemotherapy 51 2005 347 351
20. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057
22. F. Abushahin, D.K. Singh, J.R. Lurain, E.C. Grendys, A.W. Rademaker, and J.C. Schink Weekly topotecan for recurrent platinum resistant ovarian cancer Gynecol Oncol 108 2008 53 57
23. R. Morris, R.D. Alvarez, S. Andrews, J. Malone, C. Bryant, and L.K. Heilbrun Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers Gynecol Oncol 109 2008 346 352
24. Z.D. Zhong, S. Dinnogen, M. Hokom, C. Ray, D. Weinreich, and S.J. Swanson Identification and inhibition of drug target interference in immunogenicity assays J Immunol Methods 355 2010 21 28
25. M.B. Bass, S.I. Sherman, M.J. Schlumberger, M.T. Davis, L. Kivman, and H.M. Khoo Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer J Clin Endocrinol Metab 95 2010 5018 5027
26. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
27. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818
28. G. Blackledge, F. Lawton, C. Redman, and K. Kelly Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 1989 650 653
29. J. Ledermann, and F. Raja Management strategies for partially platinum-sensitive ovarian cancer Am J Cancer 5 2006 341 354
30. R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, and M. Callahan Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group Gynecol Oncol 123 2011 499 504
31. C.F. Verschraegen, S. Czok, C.Y. Muller, L. Boyd, S.J. Lee, and T. Rutledge Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer Ann Oncol 23 2012 3104 3110
32. T. Safra, S. Groshen, S. Jeffers, D.D. Tsao-Wei, L. Zhou, and L. Muderspach Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome Cancer 91 2001 90 100
33. T.J. Herzog, M.W. Sill, J.L. Walker, D. O'Malley, M. Shahin, and K. DeGeest A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group study (GOG 146Q) Gynecol Oncol 120 2011 454 458
34. B. Rini, C. Szczylik, N.M. Tannir, P. Koralewski, P. Tomczak, and A. Deptala AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 2012 6152 6161
35. M.M. Eatock, N.C. Tebbutt, C.L. Bampton, A.H. Strickland, M. Valladares-Ayerbes, and A. Swieboda-Sadlej Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer Ann Oncol 24 2013 710 718
36. B.J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, and D.S. Bae A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 European Cancer Congress 2013; Sep 27-Oct 1; Amsterdam, Netherlands 2013
37. I. Vergote, A. Oaknin Benzaquen, J. Baurain, S. Ananda, S. Wong, and X. Yang A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery Ann Oncol 23 Suppl. 9 2012
38. M. Peeters, A.H. Strickland, M. Lichinitser, A.V. Suresh, G. Manikhas, and J. Shapiro A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma Br J Cancer 108 2013 503 511
39. I.B. Vergote, A.O. Benzaquen, J. Baurain, S. Ananda, S. Wong, and X. Yang A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery Ann Oncol 23 2012 975PD
40. A.M. Poveda, F. Selle, F. Hilpert, A. Reuss, A. Pasic, and A. Savarese Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG Aurelia randomized phase III trial Ann Oncol 23 Suppl. 9 2012 LBA26